ArticleBMC cancer2020
Survival outcomes in men with a positive family history of prostate cancer: a registry based study.
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Quality of services and patient reported outcomes for prostate cancer in Tanzania: the role of patients' satisfaction from a cross-sectional study.BMC urology · 2026Article
- Family History of Early Onset or Lethal Prostate Cancer and the Risk of Prostate Cancer Death in Sweden.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Challenges of data quality for the management of prostate cancer in Tanzania: A hurdle towards improving the quality of service.PLOS global public health · 2025Article
- Effect of family history of cancer on postoperative survival in patients with non-small cell lung cancer.Translational lung cancer research · 2024Article
- Patients' perception on quality of care for prostate cancer at tertiary hospitals in Tanzania: a qualitative study.Frontiers in oncology · 2024Article
- Single nucleotide polymorphism within chromosome 8q24 is associated with prostate cancer development in Saudi Arabia.Asian journal of urology · 2024Article
- Letter to the editor for the article "Histopathological results of radical prostatectomy specimen of men younger than 50 years of age at the time of surgery: possible implications for prostate cancer screening programs?"World journal of urology · 2023Article
- Third-line treatment options in metastatic pancreatic cancer patients: a real-world study.Frontiers in oncology · 2023Article
- Prostate cancer incidence and survival in relation to prostate cancer as second cancer in relatives.Cancer medicine · 2022Article
- Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study.The Prostate · 2022Article
- Genetic predisposition to prostate cancer: an update.Familial cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the correlation between family history of prostate cancer (PCa) and survival (overall and cancer specific) in patients undergoing treatment for PCa.
methodsine thousand four hundred fifty-nine patients with PCa were extracted from the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC) database. Diagnosis occurred after 1998 and treatment before 2014. Cox proportional-hazards modeling was used to assess the effect of family history on overall survival after adjustment for confounders (age at diagnosis, NCCN risk category and year of treatment), and with stratification by primary treatment group. Competing risks regression modelling was used to assess PCa specific mortality.
resultsMen with a positive family history of PCa appear to have a lower Gleason score at the time of diagnosis (50% with Gleason < 7, compared to 39% in those without family history) and be diagnosed at a lower age (64 vs 69). Men with a positive family history of PCa appear to have better overall survival outcomes (p < 0.001, log rank test). In analysis adjusting for age at diagnosis, NCCN risk category and year of treatment, family history remained a significant factor when modelling overall survival (HR 0.72 95% CI 0.55-0.95, p = 0.021). There were no significant differences in treatment subgroups of radical prostatectomy (p = 0.7) and radiotherapy (0.054).
conclusionMen with a positive family history of PCa appear to have better overall survival outcomes. This better survival may represent lead time bias and early initiation of PSA screening. Family history of PCa was not associated with different survival outcomes in men who were treated with either radical prostatectomy or radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.